RISPERIDONE DEPOT vs ARIPIPRAZOLE: Adverse events: Specific ‐ prolactin‐related
- Population
- patients with schizophrenia
- Intervention
- RISPERIDONE DEPOT
- Comparison
- ARIPIPRAZOLE
- Outcome
- Adverse events: Specific ‐ prolactin‐related
It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Specific ‐ prolactin‐related compared with ORAL ARIPIPRAZOLE (very low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
RISPERIDONE DEPOT vs ORAL ARIPIPRAZOLE Adverse events: Specific ‐ prolactin‐related · patients with schizophrenia It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Specific ‐ prolactin‐related compared with ORAL ARIPIPRAZOLE (very low certainty). Risperidone (depot) for schizophrenia (2016) · Cochrane Headline outcomes only | RR 9.91 [2.78, 35.29] | 2 studies · 729 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
Related questions
The same intervention and outcome, asked in another population or against another comparator.
- RISPERIDONE DEPOT vs RISPERIDONE · patients with schizophrenia · 1 review
- RISPERIDONE DEPOT vs QUETIAPINE · patients with schizophrenia · 1 review
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.